These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 17522211)

  • 1. Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant.
    Opi S; Kao S; Goila-Gaur R; Khan MA; Miyagi E; Takeuchi H; Strebel K
    J Virol; 2007 Aug; 81(15):8236-46. PubMed ID: 17522211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monomeric APOBEC3G is catalytically active and has antiviral activity.
    Opi S; Takeuchi H; Kao S; Khan MA; Miyagi E; Goila-Gaur R; Iwatani Y; Levin JG; Strebel K
    J Virol; 2006 May; 80(10):4673-82. PubMed ID: 16641260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions.
    Khan MA; Goila-Gaur R; Opi S; Miyagi E; Takeuchi H; Kao S; Strebel K
    Retrovirology; 2007 Jul; 4():48. PubMed ID: 17631688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.
    Liu B; Yu X; Luo K; Yu Y; Yu XF
    J Virol; 2004 Feb; 78(4):2072-81. PubMed ID: 14747572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
    Russell RA; Pathak VK
    J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells.
    Kao S; Miyagi E; Khan MA; Takeuchi H; Opi S; Goila-Gaur R; Strebel K
    Retrovirology; 2004 Sep; 1():27. PubMed ID: 15373943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation.
    Huthoff H; Malim MH
    J Virol; 2007 Apr; 81(8):3807-15. PubMed ID: 17267497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional domains of APOBEC3G required for antiviral activity.
    Li J; Potash MJ; Volsky DJ
    J Cell Biochem; 2004 Jun; 92(3):560-72. PubMed ID: 15156567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes.
    Goila-Gaur R; Khan MA; Miyagi E; Kao S; Opi S; Takeuchi H; Strebel K
    Virology; 2008 Mar; 372(1):136-46. PubMed ID: 18023836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif.
    Kao S; Goila-Gaur R; Miyagi E; Khan MA; Opi S; Takeuchi H; Strebel K
    Virology; 2007 Dec; 369(2):329-39. PubMed ID: 17825339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production of infectious SIVagm from human cells requires functional inactivation but not viral exclusion of human APOBEC3G.
    Takeuchi H; Kao S; Miyagi E; Khan MA; Buckler-White A; Plishka R; Strebel K
    J Biol Chem; 2005 Jan; 280(1):375-82. PubMed ID: 15528183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lentiviral Vif: viral hijacker of the ubiquitin-proteasome system.
    Ehrlich ES; Yu XF
    Int J Hematol; 2006 Apr; 83(3):208-12. PubMed ID: 16720549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA and DNA binding properties of HIV-1 Vif protein: a fluorescence study.
    Bernacchi S; Henriet S; Dumas P; Paillart JC; Marquet R
    J Biol Chem; 2007 Sep; 282(36):26361-8. PubMed ID: 17609216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.
    Mehle A; Strack B; Ancuta P; Zhang C; McPike M; Gabuzda D
    J Biol Chem; 2004 Feb; 279(9):7792-8. PubMed ID: 14672928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into the dual activity of SIVmac239 Vif against human and African green monkey APOBEC3G.
    Gaur R; Strebel K
    PLoS One; 2012; 7(11):e48850. PubMed ID: 23189135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
    Stopak K; de Noronha C; Yonemoto W; Greene WC
    Mol Cell; 2003 Sep; 12(3):591-601. PubMed ID: 14527406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ubiquitination of APOBEC3 proteins by the Vif-Cullin5-ElonginB-ElonginC complex.
    Shirakawa K; Takaori-Kondo A; Kobayashi M; Tomonaga M; Izumi T; Fukunaga K; Sasada A; Abudu A; Miyauchi Y; Akari H; Iwai K; Uchiyama T
    Virology; 2006 Jan; 344(2):263-6. PubMed ID: 16303161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
    Tian C; Yu X; Zhang W; Wang T; Xu R; Yu XF
    J Virol; 2006 Mar; 80(6):3112-5. PubMed ID: 16501124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
    Sheehy AM; Gaddis NC; Malim MH
    Nat Med; 2003 Nov; 9(11):1404-7. PubMed ID: 14528300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights into the role of Vif in HIV-1 replication.
    Schröfelbauer B; Yu Q; Landau NR
    AIDS Rev; 2004; 6(1):34-9. PubMed ID: 15168739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.